The co-founder of the vaccine developer Biontech, Ugur Sahin, expects a return to normality by winter 2021, but to achieve this it is “absolutely essential” to achieve a high vaccination rate against the corona virus before autumn, he told the British television channel BBC today. However, he was optimistic that this could be achieved. The vaccine developed by Biontech and the US pharmaceutical giant Pfizer is one of the most promising products in the fight against the pandemic.
Sahin announced that the developed vaccine would be delivered as early as the end of this year or early 2021 – “if all goes well,” he added. However, he spoke of a “hard winter” and pointed out that vaccines developed soon would not yet have a major impact on the current cold season. Biontech’s goal, however, was to deliver more than 300 million doses by April: “This could already have an effect,” he said.
The Mainz-based company Biontech and its US partner Pfizer made headlines worldwide last week when they announced that their vaccine candidate had been found to be more than 90 percent effective in the ongoing clinical trial.
hp, Source: ORF.at/agencies. Picture: pixabay.com
This post has already been read 553 times!